Volume 17, Number 7—July 2011
Dispatch
Multidrug-Resistant Mycobacterium tuberculosis, Southwestern Colombia
Table 1
Family | No. (%) isolates | Patient data |
||
---|---|---|---|---|
M/F | No. with susceptible isolates/ no. with MDR isolates | No. with new treatment/ no. previously treated | ||
Beijing | 25 (15.6) | 9/16 | 1/24 | 13/11† |
LAM1 | 4 (2.5) | 4/0 | 4/0 | 4/0 |
LAM2 | 6 (3.8) | 4/2 | 3/3 | 3/2† |
LAM3 | 5 (3.1) | 2/3 | 3/2 | 3/2 |
LAM6 | 1 (0.6) | 1/0 | 1/0 | 0/1 |
LAM9 | 32 (20) | 21/11 | 24/8 | 19/12† |
H1 | 32 (20) | 17/15 | 22/10 | 15/17 |
H3 | 4 (2.5) | 2/2 | 4/0 | 4/0 |
T1 | 9 (5.6) | 4/5 | 9/0 | 8/0† |
U | 9 (5.6) | 6/3 | 2/7 | 3/6 |
U (LAM30) | 2 (1.3) | 2/0 | 2/0 | 1/1 |
X1 | 4 (2.5) | 3/1 | 1/3 | 2/2 |
X3 | 2 (1.3) | 2/0 | 2/0 | 2/0 |
Orphan1 | 1 (0.6) | 0/1 | 1/0 | 1/0 |
Orphan2 | 2 (1.3) | 0/2 | 0/2 | 1/1 |
Orphan3 | 1 (0.6) | 0/1 | 1/0 | 1/0 |
Orphan4 | 2 (1.3) | 1/1 | 0/2 | 2/0 |
Orphan5 | 1 (0.6) | 1/0 | 0/1 | 0/1 |
Orphan6 | 1 (0.6) | 0/1 | 0/1 | 1/0 |
Orphan7 | 1 (0.6) | 1/0 | 0/1 | 0/1 |
Orphan8 | 1 (0.6) | 0/1 | 0/1 | 1/0 |
Orphan9 | 1 (0.6) | 0/1 | 0/1 | 0/1 |
Orphan10 | 1 (0.6) | 1/0 | 0/1 | 0/1 |
Orphan11 | 1 (0.6) | 1/0 | 0/1 | 0/1 |
Orphan12 | 6 (3.8) | 5/1 | 0/6 | 2/4 |
Orphan13 | 1 (0.6) | 1/0 | 1/0 | 1/0 |
Orphan14 | 1 (0.6) | 1/0 | 0/1 | 0/1 |
Orphan15 | 1 (0.6) | 1/0 | 1/0 | 1/0 |
Orphan16 | 1 (0.6) | 1/0 | 1/0 | 0/0† |
Orphan17 | 2 (1.3) | 2/0 | 2/0 | 0/2 |
Total | 160 (100) | 93/67 | 84/76 | 87/68 |
*MDR, multidrug resistant.
†Complete data were not available for 5 genotypes.
Page created: August 18, 2011
Page updated: August 18, 2011
Page reviewed: August 18, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.